Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04656301 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder
A Phase 2 study, sponsored by New York State Psychiatric Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04656301 is a Phase 2 study that has completed, run by New York State Psychiatric Institute. The registered enrollment target is 12 participants.
The verdict
NCT04656301, a Phase 2 study, has completed, sponsored by New York State Psychiatric Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Followup visits to monitor safety and clinical outcome will be conducted over a 3 month period.
Interventions
- DRUG Psilocybin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2021-02-26 |
| Est. Completion | 2022-11-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04656301
The ClinicalTrials.gov registry entry for NCT04656301 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is New York State Psychiatric Institute, which has 364 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Psilocybin is the first listed.
NCT04656301 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04656301 about?
NCT04656301 is a clinical study titled "Safety and Efficacy of Psilocybin for Body Dysmorphic Disorder". In this pilot study 12 adult outpatients with body dysmorphic disorder that has not responded to at least one adequate trial of a serotonin reuptake inhibitor will be treated openly with a single oral dose of psilocybin. Followup visits to monitor safety and clinical outcome will be conducted over a...
What is the current status of trial NCT04656301?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2021-02-26. Estimated completion is 2022-11-02.
What interventions are being tested in trial NCT04656301?
The interventions under investigation include: Psilocybin (DRUG).
Who is sponsoring clinical trial NCT04656301?
This trial is sponsored by New York State Psychiatric Institute, which has 364 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.